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Orexin neurons in the hypothalamus regulate energy homeostasis by coordinating various physiological
responses. Past studies have shown the role of the orexin peptide itself; however, orexin neurons contain
not only orexin but also other neurotransmitters such as glutamate and dynorphin. In this study, we
examined the physiological role of orexin neurons in feeding behavior and metabolism by pharmaco-
genetic activation and chronic ablation. We generated novel orexin-Cre mice and utilized Cre-dependent
adeno-associated virus vectors to express Gq-coupled modiﬁed GPCR, hM3Dq or diphtheria toxin frag-
ment A in orexin neurons. By intraperitoneal injection of clozapine-N oxide in orexin-Cremice expressing
hM3Dq in orexin neurons, we could selectively manipulate the activity of orexin neurons. Pharmaco-
genetic stimulation of orexin neurons simultaneously increased locomotive activity, food intake, water
intake and the respiratory exchange ratio (RER). Elevation of blood glucose levels and RER persisted even
after locomotion and feeding behaviors returned to basal levels. Accordantly, 83% ablation of orexin
neurons resulted in decreased food and water intake, while 70% ablation had almost no effect on these
parameters. Our results indicate that orexin neurons play an integral role in regulation of both feeding
behavior and metabolism. This regulation is so robust that greater than 80% of orexin neurons were
ablated before signiﬁcant changes in feeding behavior emerged.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
The neuropeptide orexin (hypocretin) has been known to be
involved in feeding behavior since its early identiﬁcation. In 1998,
two groups independently identiﬁed this neuropeptide. One group
named it “hypocretin” as they had found the peptide in the hypo-
thalamus (De Lecea et al., 1998), and the other group named it
“orexin” due to its putative role as a regulator of feeding behavior
(Sakurai et al., 1998). Orexin is now known to regulate not only
feeding but also various phenomena including arousal, addiction,
and metabolism (Sakurai, 2007; Inutsuka and Yamanaka, 2013; De
Lecea and Huerta, 2014). Although orexin neurons exist exclusivelyarcuate nucleus; CNO, cloza-
activated by designer drugs;
ntricular; i.p., intraperitoneal;
Y; RER, respiratory exchange
: þ81 52 789 3889.
amanaka).
r Ltd. This is an open access articlein the lateral hypothalamic area (LHA), they project their axons
throughout the brain including the arcuate nucleus (Arc) where
many regulators of feeding behaviors such as proopiomelanocortin
and neuropeptide Y (NPY) neurons are present (Peyron et al., 1998;
Nambu et al., 1999). Intracerebroventricular (ICV) injection of
orexin induces feeding behavior (Sakurai et al., 1998) and water
intake (Kunii et al., 1999) in rodents. In addition, injection of orexin-
A into the rostral raphe pallidus produces a sustained increase in
brown adipose tissue thermogenesis (Tupone et al., 2011).
Although the functions of orexin peptides have already been
studied, the contribution of orexin neuronal activity to feeding
behavior remains unclear. Narcolepsy is a sleep disorder charac-
terized by primary disorganization of sleep/wakefulness cycles. In
narcoleptic patients, the number of orexin neurons is greatly
reduced, and orexin peptide levels in the cerebrospinal ﬂuid are
reduced to undetectable levels (Nishino et al., 2000; Peyron et al.,
2000; Thannickal et al., 2000). Narcoleptic patients not only
exhibit sleep fragmentation but also metabolic changes such as
increases in body weight. Interestingly, mice lacking the orexin
peptide develop narcolepsy-like symptoms (Chemelli et al., 1999),under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Fig. 1. Generation of orexin-Cre mice that express EGFP and Cre recombinase exclu-
sively in orexin neurons. A: Schematic representation of the orexin-Cre transgene. To
achieve orexin neuron-speciﬁc expression of Cre recombinase, we used a 3.2 kb 50-
upstream region of human prepro-orexin gene as a promoter. The transgene consists of
the orexin promoter, EGFP-2A-Cre cDNA, and mouse protamine intron and poly(A)
signal. Viral 2A peptide is cleaved just after translation, and EGFP and Cre recombinase
localize independently. B: Speciﬁc expression of EGFP and Cre recombinase in orexin
neurons. Immunohistochemistry showed speciﬁc expression of EGFP or Cre recombi-
nase in orexin neurons in the LHA. Quantitative analysis showed 91.2 ± 0.9% (n ¼ 8)
colocalization of Cre recombinase with orexin. Scale bars, 100 mm (upper row) and
50 mm (middle and lower row).
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phagia and late-onset obesity in addition to narcoleptic symptoms
(Hara et al., 2001). Orexin neurons express not only orexins but also
dynorphin (Chou et al., 2001) and glutamate (Abrahamson et al.,
2001). Therefore, these differences in phenotype might suggest
the involvement of other neurotransmitters besides orexin in the
regulation of feeding and energy balance. Because it is unlikely that
orexin peptides are the only factors released by orexin neurons
in vivo, it is worth investigating the effects of selective manipula-
tion of orexin neurons.
In this study, we generated a new orexin-Cre mouse line and
employed a pharmacogenetic technique called designer receptors
exclusively activated by designer drugs (DREADD) to selectively
manipulate the activity of orexin neurons in free-movingmice. This
method utilizes modiﬁed GPCRs to achieve selective, rapid and
reversible modulation of neuronal activity. In short, muscarinic
GPCRs are mutated so that their ability to bind their original ligand,
acetylcholine, is lost while the synthetic ligand clozapine-N-oxide
(CNO) can activate them (Armbruster et al., 2007). Gq-coupled
DREADD, hM3Dq activates neurons through phospholipase C-
dependent signal transduction (Alexander et al., 2009). Compared
with optogenetic techniques utilizing ion channels, activation of
GPCRs has a relatively longer effect on cellular signaling. Therefore,
it is reasonable to employ DREADD to modulate the activity of
orexin neurons for an extended time in order to examine the effects
on feeding behavior and metabolism. We also selectively ablated
orexin neurons using diphtheria toxin fragment A (DTA) to inves-
tigate the physiological roles of orexin neurons in feeding behaviors
and metabolism.
Our results show that selective activation of orexin neurons
simultaneously affects feeding behaviors and metabolism and that
only 30% of orexin neurons are required tomaintain such functions.
These ﬁndings demonstrate the robust and concurrent regulation
of feeding behaviors and wakefulness by orexin neurons.
2. Materials and methods
2.1. Animal usage
All experimental procedures involving animals were approved by the Institu-
tional Animal Care and Use Committee of Research Institute of Environmental
Medicine, Nagoya University. Mice were maintained under a strict 12 h light: dark
cycle (light period: 8:00e20:00; dark period: 20:00e8:00) in a temperature-
controlled room (22 C). Food and water were available ad libitum except for in
the experiments shown in Fig. 4. All efforts were made to minimize animal suffering
and discomfort and to reduce the number of animals used.
2.2. Generation of orexin-Cre mice
The transgene was constructed with a 3.2-kb fragment of the 50-upstream re-
gion of the human prepro-orexin gene as a promoter, Cre recombinase cDNA fused
to EGFP with the 2A peptide, and the murine protamine-1 gene intron and poly(A)
fragment (Fig. 1A). The transgene was excised and microinjected into pronuclei of
fertilized mouse eggs (C57BL/6J mice) to generate transgenic founders. Founders
were bred with C57BL/6J mice to produce stable orexin-Cre transgenic lines. Five
transgene-positive founders were obtained from the orexin-Cre transgenic mice.
Analysis of the N1 generation demonstrated that only two lines showed sufﬁcient
expression of Cre recombinase. The orexin-Cre transgenic mouse line that showed
the highest Cre expression in orexin neurons was used for subsequent experiments.
2.3. Adeno-associated virus (AAV) production and puriﬁcation
All AAV vectors were produced using the AAV Helper-Free System (Agilent
Technologies, Inc., Santa Clara, CA, USA), and puriﬁed according to published
methods (Lazarus et al., 2011). Brieﬂy, HEK293 cells were transfected with a pAAV
vector plasmid that included a gene of interest, pHelper, and pAAV-RC (serotype 10;
provided by Penn Vector Core) using a standard calcium phosphate method. Three
days later, the transfected cells were collected and suspended in artiﬁcial CSF
(124 mM NaCl, 3 mM KCl, 26 mM NaHCO3, 2 mM CaCl2, 1 mM MgSO4, 1.25 mM
KH2PO4, 10 mM D-Glucose). After 4 freezeethaw cycles, the cell lysate was treated
with benzonase nuclease (Merck, Darmstadt, Germany) at 45 C for 15 min, and
centrifuged 2 times at 16,000 g for 10 min. The supernatant was used as the virus-
containing solution. To measure the titer of puriﬁed virus dissolved in artiﬁcial CSF,quantitative PCR was performed; the virus was stored at 80 C in aliquots before
use. The pAAV-hSyn-FLEX-hM3Dq-mCherry plasmid was purchased from Addgene
(ID: 44361).
2.4. Stereotaxic AAV injection
Surgeries for AAV injections were conducted under pentobarbital anesthesia
(50mg/kg, i.p.) using a stereotaxic instrument (David Kopf Instruments, Tujunga, CA,
USA). Eight-week-old mice were injected stereotaxically into the LHA with recom-
binant AAV-hSyn-FLEX-hM3Dq-mCherry (600 nl/injection, 3  1012 copies/ml) or
AAV-hSyn-FLEX-diphtheria toxin A fragment (DTA) (600 nl/injection,
3  1012 copies/ml) with a glass micropipette and an air pressure injector system
(Pneumatic PicoPump; World Precision Instruments, Inc., Sarasota, FL, USA). Injec-
tion sites were as follows: bregma 1.5 mm, lateral ±0.7 mm, ventral 5.0 mm, for
AAV-hSyn-FLEX-hM3Dq-mCherry; and bregma 1.5 mm, lateral ±0.5 mm, ventral
5.2 mm and 4.9 mm; bregma 1.5 mm, lateral ±0.9 mm, ventral 5.0 mm, for AAV-
CMV-FLEX-DTA. Four weeks after the AAV injection, mice were analyzed using the
Comprehensive Laboratory Animal Monitoring System (CLAMS; Columbus In-
struments, Columbus, OH, USA).
2.5. Analysis of feeding behaviors and metabolism
Locomotion, food intake, water intake, and the RER were concurrently recorded
using CLAMS. CLAMS is a set of live-in cages for automated, non-invasive, and
simultaneous monitoring of horizontal and vertical activity, feeding and drinking,
oxygen consumption, and CO2 production. Twelve-week-old mice were individually
placed in CLAMS cages and monitored for more than 5 days. The ﬁrst 3 days were
used as an acclimation period. Food and water consumptionwere measured directly
Fig. 2. Pharmacogenetic activation of orexin neurons by hM3Dq. A: Schematic representation of the AAV vector expressing hM3Dq with a FLEX switch. ITR, inverted terminal
repeat; hSyn, human synapsin promoter. B: Coronal brain sections at the level of LHA, prepared from orexin-Cre mice 4 weeks after injection of AAV-hSyn-FLEX-hM3Dq-mCherry.
Immunohistochemistry showed co-localization of hM3Dq with orexin. Scale bars, 100 mm (upper row) and 50 mm (lower row). C: Whole-cell, current clamp recording from an
orexin neuron identiﬁed by mCherry ﬂuorescence from an orexin-Cre mouse injected with AAV-hSyn0FLEX-hM3Dq-mCherry. CNO (30 mM) induced rapid depolarization of
membrane potential and greatly increased the ﬁring rate. D: DMembrane potential of the neurons administered CNO. CNO did not affect the membrane potential of neurons that did
not express hM3Dq-mCherry. E: Injection of CNO in vivo induces c-Fos immunoreactivity in orexin neurons. Mice were sacriﬁced for c-Fos analysis 90 min after injection of saline or
CNO (1.0 mg/kg, i.p.). Scale bar, 50 mm. F: Quantitative analysis of c-Fos activation of neurons at ZT13.5 in orexin-Cre mice injected with the hM3Dq AAV vector and administered
saline or CNO at ZT 12 (n ¼ 7).
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consecutive horizontal beam breaks in counts) was used as the locomotion index.
Data were taken every 10 min. Only male mice were used in the experiments. Blood
glucose was measured using the ACCU-CHEK Nano meter (Roche Ltd., Basel,
Switzerland). Blood samples (5 ml) were obtained by carefully pricking the tail vein
using a sterile needle.2.6. Immunohistochemistry
The mice were deeply anesthetized with isoﬂurane and transcardially perfused
with 20 ml of chilled saline, followed by 20 ml of chilled 10% formalin solution
(Wako Pure Chemical Industries, Ltd., Osaka, Japan). The brain was removed, post-
ﬁxed in 10% formalin solution at 4 C overnight, and immersed in 30% sucrose in
PBS at 4 C for at least 2 days. A series of 40 mm sections were obtained with a
cryostat (Leica CM3050 S; Leica Microsystems, Wetzlar, Germany).
For staining, coronal brain sections were immersed in blocking buffer (1% BSA
and 0.25% Triton-X in PBS), then incubated with primary antibodies at 4 C over-
night. The sections were washed with blocking buffer then incubated with sec-
ondary antibodies for 1 h at RT. The brain sections were mounted and examined
with a ﬂuorescence microscope (BZ-9000, Keyence, Osaka, Japan or IX71, Olympus,
Tokyo, Japan). Primary antibodies and secondary antibodies were diluted in blocking
buffer as follows: anti-Cre recombinase rabbit antibody (Clontech Laboratories, Inc.,
Mountain View, CA, USA) at 1:500, anti-c-Fos rabbit antibody (Santa Cruz Biotech-
nology, Inc., Dallas, TX, USA) at 1:500, anti-orexin-A goat antibody (Santa Cruz) at
1:2000, anti-MCH rabbit antibody (SigmaeAldrich, St. Louis, MO, USA) at 1:2000, CF
488-conjugated anti-mouse or anti-rabbit antibody (Biotium Inc., Hayward, CA,
USA) at 1:1000, CF 594-conjugated anti-rabbit or anti-goat antibody (Biotium) at
1:1000 and CF 647-conjugated anti-goat antibody (Biotium) at 1:1000.2.7. Electrophysiology
Three-week-old orexin-Cre mice were injected with AAV-hSyn-FLEX-hM3Dq-
mCherry and sacriﬁced at 10 weeks of age. The mice were deeply anesthetized
with isoﬂurane (Abbott Japan, Tokyo, Japan) and decapitated. Brains were quickly
isolated in ice-cold cutting solution consisting of (in mM): 280 sucrose, 2 KCl, 10
HEPES, 0.5 CaCl2,10MgCl2, 10 glucose, pH 7.4 with NaOH, bubbled with 100% O2, and
immediately cut coronally into 350 mm-thick slices with a microtome (VTA-1200S,
Leica Microsystems, Wetzlar, Germany). Slices containing the LHA were transferred
to an incubation chamber ﬁlled with physiological solution containing (in mM): 135
NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, pH 7.4 with NaOH, bubbled with
100% O2. The brain slices were then transferred to a recording chamber (RC-27L,
Warner Instruments, Hamden, CT, USA) on a ﬂuorescence microscope stage
(BX51WI; Olympus, Tokyo, Japan). The ﬂuorescence microscope was equipped with
an infrared camera (C2741-79; Hamamatsu Photonics, Hamamatsu, Japan) for
infrared differential interference contrast imaging and a CCD camera (IK-TU51CU,
Olympus, Tokyo, Japan). Neurons with mCherry ﬂuorescence were categorized as
orexin neurons and were subjected to electrophysiological recordings. Recordings
were performed with an Axopatch 200B ampliﬁer (Molecular Devices LLC, Sunny-
vale, CA, USA) using a borosilicate pipette (GC150-10; Harvard Apparatus, Holliston,
MA, USA) prepared by a micropipette puller (P-1000; Sutter Instruments, Novato,
CA, USA) ﬁlled with intracellular solution (4e10 MU), consisting of the following (in
mM): 138 K-gluconate, 8 NaCl,10 HEPES, 0.2 EGTA-Na3, 2MgATP, and 0.5 Na2GTP, pH
7.3 with KOH. During recordings, cells were superfused with extracellular solution at
a rate of 1.6 ml/min using a peristaltic pump (Dynamax; Rainin Instrument LLC,
Oakland, CA, USA). CNO (SigmaeAldrich) was dissolved in extracellular solution at a
concentration of 30 mM and applied by local application through a ﬁne tube (100 mm
diameter) positioned near the recording neurons. The output signal was low-pass
ﬁltered at 5 kHz and digitized at 10 kHz. Data were recorded on a computer
through a Digidata 1322A A/D converter using pClamp software (version 10;
Fig. 3. Transient activation of orexin neurons alters locomotion, food intake, water intake and RER. Orexin-Cre or wild type mice were injected with AAV-hSyn-FLEX-hM3Dq-
mCherry in the LHA. After 4 weeks, to allow for gene expression, they were injected with CNO (1.0 mg/kg, i.p.) or saline at 12:00 (ZT4). All mice were monitored using a
comprehensive laboratory animal monitoring system (CLAMS), which continuously records activity. AeC: Ambulatory locomotion activity, DeF: Food intake, GeI: Water intake, and
JeL: Respiratory exchange ratio. Data measured during 10 min intervals are plotted as mean ± SEM (WT, n¼ 15; Tg, n¼ 9) in the left and middle columns. The summation (C, F and I)
or average (L) of each plot during the 4 h (from ZT 4 to ZT 8) is analyzed in the right column. The data were analyzed by one-way ANOVA followed by TukeyeKramer multiple
comparison tests.
Fig. 4. Transient activation of orexin neurons alters blood glucose in fasting mice. Orexin-Cre or wild type mice were injected with AAV-hSyn-FLEX-hM3Dq-mCherry in the LHA at 8
weeks old. After 4 weeks they were injected with CNO (1.0 mg/kg, i.p.) or saline at 12:00 (ZT4). Measurements at 12:00 were done just before CNO/saline injection. All the mice
were fasted from 20:00 (ZT12) on the day before the experiments. A, B: The time course of fasting blood glucose before and after i.p. injection of saline or CNO into orexin-Cre and
wild type mice infected with AAV vectors. Measured data are plotted as mean ± SEM (WT, n ¼ 15; Tg, n ¼ 9). C: Quantitative analysis of average blood glucose during 4 h from ZT5 to
ZT8. The data were analyzed by one-way ANOVA followed by TukeyeKramer tests.
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(LightStone, Tokyo, Japan) and Canvas14 software (ACD Systems, Victoria, Canada).
2.8. Statistics
Statistical analyses were performed using ORIGIN 9 software (LightStone).
Simple comparisons of the means and SEM were performed by Student's t-test.
Multiple comparisons of the means and SEM were performed by one-way ANOVA
analyses followed by TukeyeKramer post-hoc tests. A P value of less than 0.05 was
considered signiﬁcant in these studies.
3. Results
3.1. Cre recombinase is exclusively expressed in orexin neurons in
novel orexin-Cre mice
To achieve speciﬁc expression in orexin neurons, we ﬁrst
generated a novel orexin-Cre mouse line. The utility of the 3.2 kb
fragment of the 50-upstream region of the human prepro-orexin
gene for expressing genes of interest in orexin neurons has been
previously reported (Sakurai et al., 1999; Moriguchi et al., 2002;
Tsunematsu et al., 2011), so we employed this sequence as a pro-
moter (Fig.1A). The Cre recombinase was fused to EGFP with a self-
cleaving 2A peptide from the Thosea asigna virus to easily recognize
orexin neurons by ﬂuorescence without immunostaining. The viral
2A peptide is immediately cleaved upon translation, which allows
expression of multiple proteins from a single ORF (Szymczak et al.,
2004). The transgene was excised and microinjected into pronuclei
of fertilized C57BL/6J mouse eggs to generate transgenic founders.
Founders were bred with C57BL/6J mice to produce stable orexin-
Cre transgenic lines. Five transgene-positive founders were ob-
tained from the orexin-Cre transgenic mice. Analysis of the N1
generation demonstrated that only two lines showed sufﬁcient
expression of Cre recombinase. The orexin-Cre transgenic line that
showed the highest Cre expression in orexin neurons was used in
subsequent experiments.
Histological sections were examined from regions throughout
the brain of orexin-Cremice, and EGFP-expressing cells were found
exclusively in the LHA. Immunohistochemistry with anti-Cre
recombinase and anti-orexin-A antibody showed 91.2 ± 0.9%
(n ¼ 8) co-localization of Cre recombinase with orexin (Fig. 1B). No
ectopic expression of EGFP or Cre recombinase was observed. Note
that Cre recombinase was localized to the nucleus because of its
nuclear localization signal at the N-terminus, while EGFP was
localized throughout the soma. This ﬁnding demonstrates their
successful separation by 2A peptide cleavage.
3.2. Expression and pharmacogenetic activation of hM3Dq in orexin
neurons
To selectively manipulate activity of orexin neurons, we
employed designer receptors exclusively activated by designer
drugs (DREADD) technology. We used a Cre-dependent adeno-
associated viral vector to speciﬁcally target the stimulatory hM3Dq
DREADD to orexin neurons. The hM3Dq receptor has a high afﬁnity
for the synthetic ligand CNO (Alexander et al., 2009), and CNO
administration can induce depolarization and ﬁring of hM3Dq-
expressing neurons. Stable transgene inversion was achieved by
employing a FLEX (ﬂip-excision) switch. The FLEX switch consists
of paired loxP and lox2272 sequences and enables the expression of
a gene of interest only when Cre recombinase is present (Atasoy
et al., 2008) (Fig. 2A). Fused mCherry was used to monitor the
expression of hM3Dq.
AAV-hSyn-FLEX-hM3Dq-mCherry was stereotaxically injected
into the LHA of eight-week-old orexin-Cre mice, and mice were
sacriﬁced 4 weeks after injection. Immunohistochemistry showed
that hM3Dq was expressed exclusively in orexin neurons (Fig. 2B).Using fused mCherry as a marker, 71.3 ± 6.8% (n ¼ 7) of orexin
neurons were shown to express hM3Dq-mCherry.
We then performed whole-cell current clamp recordings to
determine the ability of hM3Dq to activate orexin neurons in vitro.
Orexin-Cre mice were injected with AAV-hSyn-FLEX-hM3Dq-
mCherry in the LHA at 3 weeks of age, and were sacriﬁced 7
weeks after injection to obtain brain slices. Neurons strongly
expressing mCherry were considered to be orexin neurons and
were subjected to whole-cell recordings. Local application of CNO
(30 mM) to brain slices greatly increased the ﬁring rate of orexin
neurons (Fig. 2C). This CNO-induced depolarization was sustained
for about 10 min after washout, and was reversible. We also
conﬁrmed that application of CNO did not affect the membrane
potential of orexin neurons not expressing hM3Dq-mCherry
(P < 0.01; Student's t-test; n ¼ 5) (Fig. 2D).
Next, we checked the neuronal activation by hM3Dq in vivo.
Neuronal activity of orexin neurons changes in accordance with
arousal state; c-Fos expression in orexin neurons is low during the
light period and high during the dark period (Estabrooke et al.,
2001). Therefore, we examined the effects of excitatory hM3Dq
DREADD during the light period when daily activity of orexin
neurons is at its lowest. Orexin-Cre mice were injected with AAV-
hSyn-FLEX-hM3Dq-mCherry into the LHA at 8 weeks of age. Wild
type mice were also injected with the same AAV vectors as a con-
trol. 4 weeks after stereotaxic injection, mice were administered
CNO (1.0 mg/kg) by i.p. injection at 12:00 (ZT4), and sacriﬁced at
13:30 (ZT5.5). We found that i.p. injection of CNO greatly increased
c-Fos immunoreactivity in orexin neurons expressing hM3Dq-
mCherry (Fig. 2E). Quantitative analyses showed that 55.1 ± 8.5%
of orexin-ir neurons expressed c-Fos in orexin-Cre mice injected
with CNO (n ¼ 7). This expression level of c-Fos was much higher
than that in the mice administered saline (14.7 ± 3.3%) (P < 0.01;
Student's t-test; n ¼ 7) (Fig. 2F). Note that the c-Fos expression rate
was increased to 86.7 ± 7.2% if orexin-ir neurons expressing
hM3Dq-mCherry were analyzed (n ¼ 7) (Fig. 2F). In wild type mice
infected with AAV-hSyn-FLEX-hM3Dq-mCherry, no expression of
mCherry was detected. We also conﬁrmed that c-Fos immunore-
activity showed no difference between the wild type mice injected
with CNO and saline (data not shown).
3.3. Activation of orexin neurons alters feeding behaviors and
metabolism
After the conﬁrmation of selective activation of orexin neurons,
we examined the effects of pharmacogenetic activation of orexin
neurons on feeding behaviors and metabolism. We employed a
CLAMS to simultaneously monitor locomotion, food intake, water
intake, and respiratory exchange ratio. The effects of hM3Dq were
examined at 12:00 (ZT4) when the activity of orexin neurons is
lowest. Saline injection into orexin-Cre mice expressing hM3Dq-
mCherry (Tg) was used as the control, and CNO injection into
wild-type mice infected with AAV-hSyn-FLEX-hM3Dq-mCherry
(WT) was used as an additional control.
Although i.p. injection of saline activated locomotor activity in
control mice during the ﬁrst 30 min after injection (Fig. 3A),
stimulation of orexin neurons by i.p. injection of CNO (1.0 mg/kg)
induced a signiﬁcantly greater increase in locomotion compared
with controls (Fig. 3B). This increase in locomotion started imme-
diately after injection, and was sustained for about 4 h. One-way
ANOVA and TukeyeKramer post-hoc tests showed that CNO
administration into Tg mice signiﬁcantly increased locomotor ac-
tivity during the 4 h after injection (P < 0.001;WT, n¼ 15; Tg, n¼ 9)
(Fig. 3C). The total number of locomotive counts among Tg mice
injected with CNO was 4-fold more than in controls (Tg þ CNO;
4206 ± 1045 counts, Tg þ Saline; 1295 ± 148 counts).
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injection of saline into WT and Tg mice induced only weak effects
on feeding (Fig. 3D), CNO administration into Tg mice rapidly
increased food intake (Fig. 3E). This rapid increase in food intake
was ﬁrst recorded within 10 min after injection, and was sustained
for approximately 4 h (Fig. 3E). One-way ANOVA and TukeyeK-
ramer post-hoc tests showed that CNO administration into Tg mice
resulted in a signiﬁcant increase in food intake during the 4 h after
injection (P < 0.001; WT, n ¼ 15; Tg, n ¼ 9) (Fig. 3F). The average
food intake in orexin neuron-activated mice was 5-fold greater
than in saline controls (Tg þ CNO; 1.14 ± 0.08 g, Tg þ Saline;
0.23 ± 0.04 g).
The effect of pharmacogenetic activation of orexin neurons on
water intake was more prominent. Saline injection resulted in
almost no change (Fig. 3G), while i.p. injection of CNO into Tg mice
induced a strong increase in water intake (Fig. 3H). The increase in
water intake also started within the ﬁrst 10 min after injection, and
was sustained for about 4 h, similar to the changes in locomotion
and food intake. One-way ANOVA and TukeyeKramer post-hoc
tests showed that CNO administration into Tg mice signiﬁcantly
increasedwater intake during the 4 h after injection (P < 0.001;WT,
n ¼ 15; Tg, n ¼ 9) (Fig. 3I), and the average water intake in orexin
neuron-activated mice was 10-fold greater than in saline controls
(Tg þ CNO; 1.64 ± 0.31 ml, Tg þ Saline; 0.16 ± 0.03 ml).
We also found that CNO injection alters metabolic parameters in
Tg mice. Injection of saline into Tg mice or CNO injection into WT
mice had little effect on the respiratory exchange ratio (RER)
(Fig. 3J). In contrast, RER strongly increased after injection of CNO in
Tg mice. This change was not as pronounced as the change in
locomotion or feeding, but continued even after the change in
locomotion had returned to basal levels (Fig.3K). One-way ANOVA
and TukeyeKramer post-hoc tests showed that CNO administration
into hM3Dq-expressing mice signiﬁcantly increased average RER
during the 4 h after injection (P < 0.001; WT, n ¼ 15; Tg, n ¼ 9)
(Fig. 3L).
To examine metabolic changes, we also investigated blood
glucose levels in transgenic mice. Because pharmacogeneticFig. 5. Selective ablation of orexin neurons by DTA. A: Schematic representation of double-
human synapsin promoter. B: Coronal brain sections at the level of LHA, prepared from or
showed that orexin neurons were strongly ablated, while MCH neurons were intact at the s
weeks after the injection of AAV-CMV-FLEX-DTA into orexin-Cre mice. 83.0 ± 1.7% (n ¼ 8)
compared with control mice. The data were analyzed by Student's t-test.activation of orexin neurons increases food intake, we removed
access to food at 20:00 on the day before the investigation to
exclude indirect effects of food digestion on blood glucose levels.
We found that i.p. injection of CNO (1.0 mg/kg) increased blood
glucose independently from food intake (Fig. 4B) and this effect was
maintained for about 6 h. In contrast, injection of saline intoTgmice
or CNO into WT mice had little effect on blood glucose levels
(Fig. 4A). ANOVA and Tukey's post-hoc tests showed that CNO
administration into hM3Dq-expressing mice resulted in a signiﬁ-
cant increase in the AUC (area under the curve) during the 6 h after
injection (P < 0.001; WT, n ¼ 15; Tg, n ¼ 9) (Fig. 4C).
3.4. Selective ablation of orexin neurons by DTA
To investigate the physiological role of orexin neurons in feeding
and metabolism, we employed selective ablation of orexin neurons
using DTA.We produced Cre-dependent AAV vectors that selectively
induce DTA expression only in cells expressing Cre recombinase
(AAV-CMV-FLEX-DTA) (Fig. 5A). DTA catalyzes ADP-ribosylation of
eukaryotic elongation factor 2 (Oppenheimer and Bodley, 1981), and
causes cell death by inhibiting protein synthesis. We stereotaxically
injected AAV-CMV-FLEX-DTA vectors into the LHA of eight-week-old
orexin-Cre mice, and sacriﬁced them 4 weeks after injection.
Immunohistochemistry with anti-orexin-A antibody showed strong
ablation of orexin neurons (Fig. 5B). To conﬁrmwhether this ablation
of orexin neurons was selective, we also performed immunostaining
of melanin-concentrating hormone (MCH) neurons as a control.
MCH neurons are also localized in the LHA similar to orexin neurons,
although their localization is completely segregated. We found that
MCH neurons were mostly intact, while orexin neurons were
strongly ablated at the same position (Fig. 5B).
We divided orexin neuron-ablated mice into 2 groups since we
used 2 different lots of AAV-CMV-FLEX-DTA and there were dif-
ferences in the resulting extent of ablation. One group was labeled
“DTA (70%)” mice as 69.6 ± 2.4% of orexin neurons were ablated in
this group, n ¼ 8; the other group was labeled “DTA (83%)” mice as
83.0 ± 1.7% of orexin neurons were ablated in this group, n ¼ 8.ﬂoxed Cre-dependent AAV vector expressing DTA. ITR, inverted terminal repeat; hSyn,
exin-Cre mice 4 weeks after injection of AAV-CMV-FLEX-DTA. Immunohistochemistry
ame position. C: Quantitative analysis of the number of orexin and D: MCH neurons 4
of orexin neurons were ablated, while the number of MCH neurons did not change
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in DTA (83%) mice did not change signiﬁcantly compared with
control mice (93.4 ± 3.2%, n ¼ 8) (Fig. 5C and D).
3.5. Feeding behaviors and metabolism in orexin neuron-ablated
mice
After the conﬁrmation of selective ablation of orexin neurons,
we examined feeding behaviors and metabolism in these orexin
neuron-ablated mice using CLAMS. Eight-week-old orexin-Cremice
injected with AAV-CMV-FLEX-DTA (DTA (70%) mice and DTA (83%)
mice) or AAV-CMV-FLEX-mCherry vectors (control mice) were
analyzed by CLAMS at 12 weeks of age. At least 3 days were allowed
for acclimation before sampling the data.
We found that the time course of locomotion in DTA (83%) mice
was similar to that in control mice. No strong reciprocal changes
between the dark and light periods were observed. Quantitative
analysis of total locomotive activity showed a weak decreasing
trend in both the light period and dark period, although these
differences were not statistically signiﬁcant (Fig. 6A).
DTA (83%) mice showed a signiﬁcant decrease in food intake
during the light period (one-way ANOVA and TukeyeKramer post-Fig. 6. Ablation of orexin neurons by DTA diminished food intake and water intake. Orexin-C
(DTA) in the LHA. After 4 weeks, to allow for gene expression, they were analyzed using
records activity. A: Ambulatory locomotion activity, B: Food intake, and C: Water intake. Me
(from ZT 0 to 12), DP (from ZT 12 to 24), and throughout an entire day were analyzed by one
and water intake.hoc tests; P < 0.05; n ¼ 8) (Fig. 6B). The total amount of food intake
by DTA (83%) mice during the dark period was also lower compared
to controls, although the difference was not signiﬁcant. Note that
changes in food intake in DTA (83%)mice during the transition from
the light to dark period were slightly reduced compared with
control mice.
Most strikingly, water intake was strongly reduced in DTA (83%)
mice throughout the entire day (one-way ANOVA and TukeyeK-
ramer post-hoc tests; P < 0.05; n¼ 8) (Fig. 6C). This overall decrease
in water intake was largely attributed to a decrease during the dark
period (one-way ANOVA and TukeyeKramer post-hoc tests;
P < 0.01; n ¼ 8), although water intake during the light period was
also less than in control mice. Locomotion, food intake, and water
intake in DTA (70%) mice were not signiﬁcantly changed compared
with control mice (Fig. 6A, B and C). Note that these reductions in
food and water intake were present even though the average body
weight of DTA (83%) mice was signiﬁcantly larger than control mice
(P < 0.01; n¼ 8; one-way ANOVA followed by TukeyeKramer tests)
(Fig. 7A). Body weight was measured at 12 weeks of age, 4 weeks
after injection of AAV vectors. In addition, blood glucose levels of
DTA (83%) and DTA (70%) mice were lower than control mice
(Fig. 7B).re mice were injected with AAV-hSyn-FLEX-mCherry (Control) or AAV-CMV-FLEX-DTA
a comprehensive laboratory animal monitoring system (CLAMS), which continuously
asured data are plotted as mean ± SEM (n ¼ 8). The summations of each plot during LP
-way ANOVA followed by TukeyeKramer tests. DTA (83%) mice showed decreased food
Fig. 7. Ablation of orexin neurons affects blood glucose and body weight. Orexin-Cre mice were injected with AAV-hSyn-FLEX-mCherry (Control) or AAV-CMV-FLEX-DTA (DTA)
vectors in the LHA. After 4 weeks they were measured. A: Body weight and B: blood glucose. Measured data are plotted as mean ± SEM (n ¼ 8). The data were analyzed by one-way
ANOVA followed by TukeyeKramer tests.
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The orexin system has been implicated in feeding behaviors and
metabolism. ICV administration of orexin peptides induces feeding
(Sakurai et al., 1998) and drinking behavior (Kunii et al., 1999) and
also increases blood glucose via the sympathetic pathway (Yi et al.,
2009). Our results using pharmacogenetics fundamentally conﬁrm
these roles in feeding and metabolism, but also indicate new in-
sights that are described below. In addition, stable speciﬁc
expression of Cre-dependent AAV vectors shows that our new
orexin-Cre mice are a valuable tool for manipulating the orexin
system in vivo.
4.1. The effects of manipulating orexin neuronal activity by
DREADD
In this study we achieved selective activation of orexin neurons
using pharmacogenetics. Stereotaxic injection of the AAV vector
into the LHA of orexin-Cre mice induced sufﬁcient expression of
hM3Dq exclusively in orexin neurons, and neuronal activation by
CNO was conﬁrmed by electrophysiology and c-Fos immunohis-
tochemistry. Activation of orexin neurons induced concurrent in-
creases in locomotion, food intake, and water intake, and affected
metabolic factors such as respiratory exchange ratio and blood
glucose level. These ﬁndings enhance our understanding of the
integrative function of orexin neurons on feeding and metabolism.
As far as we know, this is the ﬁrst study to comprehensively
investigate the effects of manipulating orexin neuronal activity on
feeding and metabolism.
The induction of elevated food and water intake was sustained
for at least 4 h. It has been reported that activation of food and
water intake by ICV administration of orexin peptides returned to
baseline within 2 h (Kunii et al., 1999). Because the CNO (1.0 mg/kg;
i.p.) used in this study is supposed to be cleared from blood plasma
within 2 h (Guettier et al., 2009), it is possible that the longer-
lasting effects of pharmacogenetic activation on feeding behaviors
is derived from the activity of co-factors released along with
orexins. However, other alternative explanations should be care-
fully considered. It was reported that activation of forebrain prin-
cipal neurons by hM3Dq can induce very long effects on locomotion
up to 9 h (Alexander et al., 2009). It was also reported that
carbachol-induced gamma rhythm in hippocampal slices persists
even after the removal of carbachol from the bath (Fisahn et al.,
1998). Therefore, transient activation of muscarinic receptors (and
hM3Dq) can induce persistent responses in some neurons.
The effect on blood glucose might be derived from activation of
sympathetic nerves. Orexin can inﬂuence liver function via the
sympathetic pathway (Van DenTop et al., 2003) and it has also beenreported that the stimulatory effect on blood glucose by ICV
administration of orexin-A was prevented by hepatic sympathetic
denervation (Yi et al., 2009). Therefore, it is also possible that the
sustained effects on blood glucose and RER by CNO result from the
involvement of indirect signal transduction downstream of orexin
neurons.4.2. Sustained in vivo manipulation of metabolism by DREADD
Recently, a growing number of optogenetic studies have
revealed the physiological functions of orexin neurons in the
regulation of sleep and arousal (Adamantidis et al., 2007;
Tsunematsu et al., 2011; Carter et al., 2012). However, it is difﬁ-
cult to alter sustained neuronal activity over a few hours using
optogenetics due to inactivation of photo-activated channels or
pumps. For example, our group found that optogenetic inhibition of
orexin neurons by halorhodopsin was only sustained for a few
minutes (Tsunematsu et al., 2011). Arch or ArchT are more stable
than halorhodopsin, but they are still not able to inhibit neuronal
activity for multiple hours. In addition, optogenetic activation de-
polarizes neurons in an extremely synchronized manner, which is
not likely to happen under physiological conditions. Furthermore,
channelrhodopsin2 is much more permeable to Hþ than Naþ, and
its activation can induce intracellular acidiﬁcation and affect
cellular signaling (Beppu et al., 2014). Given these limitations of
optogenetics, DREADD is a valuable alternative tool for manipu-
lating endogenous signaling, although its time resolution is not as
high.
In this study, pharmacogenetic activation of orexin neurons
could alter RER and blood glucose for as long as 6 h. It was reported
that cholecystokinin (CCK) activates orexin neurons through the
cholecystokinin A receptor (Tsujino et al., 2005). CCKA couples with
the Gq subclass of G-proteins, and subsequently depolarizes
membrane potential via activation of non-selective cation channels,
likely TRP channels in orexin neurons. These pathways might be
involved in hM3Dq-mediated activation of orexin neurons since
hM3Dq is reported to activate the endogenous Gq pathway. The
longer term effects and the facility of pharmacogenetics are suit-
able for various behavioral testing and physiological experiments
(Ray et al., 2011; Krashes et al., 2013). Recently it was shown that
manipulation of orexin neuronal activity by DREADD can affect
states of sleep/wakefulness (Sasaki et al., 2011). Our study extends
the application of DREADD to additional behaviors including
feeding and metabolism. In addition, this pharmacogenetic tech-
nique does not require optic ﬁbers for stimulation, so it is suitable
for usage in closed cages for monitoring metabolic factors such as
O2 consumption or CO2 emission.
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Previous studies have shown that ablation of orexin neurons
induces severe fragmentation of sleep/wakefulness cycles and late-
onset obesity (Hara et al., 2001). Therefore, it is surprising that a
70% ablation of orexin neurons showed almost no change in these
parameters. This ﬁnding implies that only a small percentage of
orexin neurons are required to maintain their function in wake-
fulness, feeding behaviors, and metabolic regulation. It is known
that more than 70% of dopaminergic neurons are lost in the sub-
stantia nigra pars compacta before the onset of Parkinson's disease
(Lang and Lozano, 1998). In addition, postmortem studies of
narcoleptic subjects indicated an 80e100% reduction in the number
of orexin neurons, determined by in situ hybridization (Peyron
et al., 2000). These ﬁndings suggest the robust regulation of
feeding behavior and metabolism by orexin neurons.
Conversely, pharmacogenetic activation of orexin neurons
showed strong effects, although the expression rate of hM3Dq was
lower than that of DTA. It has been reported that orexin neurons
express orexin receptors and can be activated by orexin peptides
(Yamanaka et al., 2010). This positive feedback might explain the
strong effects of pharmacogenetically activating orexin neurons
observed in our study. It was reported that chronic administration
of orexin-A does not affect body weight, although it increases
daytime food intake (Yamanaka et al., 1999). Therefore, it is possible
that chronic activation of the orexin system might not be sufﬁcient
to overcome the strong homeostasis of body weight in vivo.
It is also intriguing that an 83% loss of orexin neurons decreased
feeding behaviors, while the pattern of locomotion in the mice
remained intact. Various effects on feeding behaviors and physio-
logical responses by orexin administration are sometimes regarded
as the results of changes in wakefulness. However, the early
emerging changes in food and water intake suggest that orexin
neurons directly regulate feeding behaviors. In addition, we
observed the ﬁrst changes in locomotion and food or water intake
simultaneously within 10 min after injection. These results also
show that the changes in feeding by manipulation of orexin
neuronal activities are not indirect effects induced by changes in
sleep/wakefulness. Taken together, our ﬁndings indicate the robust
and concurrent regulation of feeding behaviors and metabolism by
orexin neurons.
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